

Primary Myelofibrosis- Market Insights, Epidemiology and Market Forecast 2028

<https://marketpublishers.com/r/P07E29BE16EEN.html>

Date: June 2019

Pages: 98

Price: US\$ 5,980.00 (Single User License)

ID: P07E29BE16EEN

Abstracts

Report Summary

'Primary Myelofibrosis- Market Insights, Epidemiology and Market Forecast 2028' report provides the detailed overview of the disease and in depth understanding of historical and forecasted epidemiology. It highlights the existing treatment patterns, potential upcoming drugs and also identifies best of the market opportunities by providing the current and forecasted market revenue, sales trends, and drug uptake during the study period from 2016-2028.

Market Segment by Countries, covering?

United States

EU5 (Germany, France, Italy, Spain and the United Kingdom)

Japan

Study Period: 2016-2028

Primary Myelofibrosis Understanding and Treatment Algorithm

The report provides the in depth analysis of the disease overview by providing details such as disease definition, classification, symptoms, etiology, pathophysiology and diagnostic trends. The comprehensive details about treatment algorithms and treatment guidelines for Primary Myelofibrosis in the US, Europe, and Japan are also provided in the report.

Primary Myelofibrosis Epidemiology

This section provide the insights about historical and current patient pool and forecasted trend for 7 major markets. It takes in to account the analysis of numerous studies,

survey reports as well as KOL's views which helps to recognize the factors behind the current and forecasted trends, diagnosed and treatable patient pool along with assumptions undertaken.

Primary Myelofibrosis Product Profiles & Analysis

This part of the Primary Myelofibrosis report encloses the detailed analysis of marketed drugs and Phase III and late Phase II pipeline drugs. It provides the key cross competition which evaluates the drugs on several parameters including, safety & efficacy results, mechanism of action, route, launch dates and designations. This section also covers the market intelligence and tracking of latest happenings, agreements and collaborations, approvals, patent details and other major breakthroughs.

Primary Myelofibrosis Market Outlook

The Primary Myelofibrosis market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. This segment analyses the market trend of each marketed drug and late-stage pipeline drugs. This is done by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders . The calculated market data is presented with relevant tables and graphs to give a clear view of the market at first sight.

Primary Myelofibrosis Market Share by Therapies

This section focusses on the rate of uptake of the potential drugs recently launched or will be launched in the market during the study period from 2016-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug. This information also helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It provides the comparison of the drugs on the basis of market share and size. This analysis helps in investigating factors important in market uptake and in making financial as well as regulatory decisions.

Primary Myelofibrosis Report Insights

Patient Population in Primary Myelofibrosis

Therapeutic Approaches in Primary Myelofibrosis

Primary Myelofibrosis Pipeline Analysis

Primary Myelofibrosis Market Size and Trends
Primary Myelofibrosis Market Opportunities
Impact of upcoming Therapies in Primary Myelofibrosis

Primary Myelofibrosis Report Key Strengths
10 Year Forecast
7MM Coverage
Epidemiology Segmentation
Drugs Uptake
Highly Analyzed Market
Key Cross Competition

Primary Myelofibrosis Report Assessment
Current Treatment Practices in Primary Myelofibrosis
Unmet Needs in Primary Myelofibrosis
Detailed Primary Myelofibrosis Pipeline Product Profiles
Market Attractiveness
Market Drivers and Barriers

Key Benefits

This report will help to develop Business Strategies by understanding the trends shaping and driving the Primary Myelofibrosis market
Organize sales and marketing efforts by identifying the best opportunities for Primary Myelofibrosis market
To understand the future market competition in the Primary Myelofibrosis market.

Note: We understand the needs of the rapidly changing market and is helping the client by providing the most up to date Report. It usually takes 4-5 days to deliver this kind of Report. The report coverage will depend on the availability of the data.

Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Contents

1 KEY INSIGHTS

2 PRIMARY MYELOFIBROSIS MARKET OVERVIEW AT A GLANCE

2.1 Market Share (%) Distribution of Primary Myelofibrosis in 2018

2.2 Market Share (%) Distribution of Primary Myelofibrosis in 2028

3 PRIMARY MYELOFIBROSIS: DISEASE BACKGROUND AND OVERVIEW

3.1 Introduction

3.2 Symptoms

3.3 Etiology

3.4 Risk Factor

3.5 Pathophysiology

3.6 Diagnosis

3.7 Treatment

4 EPIDEMIOLOGY AND PATIENT POPULATION

4.1. Key Findings

4.2. Total Prevalent/ Incident Patient Population of Primary Myelofibrosis in 7MM

4.3. Total Prevalent Patient Population of Primary Myelofibrosis in 7MM – By Countries

5 EPIDEMIOLOGY OF PRIMARY MYELOFIBROSIS BY COUNTRIES (2016-2028)

5.1 United States- Epidemiology (2016-2028)

5.1.1 Assumptions and Rationale

5.1.2 Prevalent/Incident Cases of Primary Myelofibrosis in the United States

5.1.3 Sub-Type Specific cases of Primary Myelofibrosis in the United States

5.1.4 Sex- Specific Cases of Primary Myelofibrosis in the United States

5.1.5 Diagnosed Cases of Primary Myelofibrosis in the United States

5.1.6 Treatable Cases of Primary Myelofibrosis in the United States

5.2 EU5 Countries

5.2.1 Germany

5.2.1.1 Assumptions and Rationale

5.2.1.2 Prevalent/Incident Cases of the of Primary Myelofibrosis in the Germany

5.2.1.3 Sub-Type Specific cases of Primary Myelofibrosis in the Germany

5.2.1.4 Sex- Specific Cases of the Primary Myelofibrosis in the Germany

5.2.1.5 Diagnosed Cases of the Primary Myelofibrosis in the Germany

5.2.1.6 Treatable Cases of the Primary Myelofibrosis

5.2.2 France

5.2.2.1 Assumptions and Rationale

5.2.2.2 Prevalent/Incident Cases of the of Primary Myelofibrosis in the France

5.2.2.3 Sub-Type Specific cases of Primary Myelofibrosis in the France

5.2.2.4 Sex- Specific Cases of the Primary Myelofibrosis in the France

5.2.2.5 Diagnosed Cases of the Primary Myelofibrosis in the France

5.2.2.6 Treatable Cases of the Primary Myelofibrosis

5.2.3 Italy

5.2.3.1 Assumptions and Rationale

5.2.3.2 Prevalent/Incident Cases of the of Primary Myelofibrosis in the Italy

5.2.3.3 Sub-Type Specific cases of Primary Myelofibrosis in the Italy

5.2.3.4 Sex- Specific Cases of the Primary Myelofibrosis in the Italy

5.2.3.5 Diagnosed Cases of the Primary Myelofibrosis in the Italy

5.2.3.6 Treatable Cases of the Primary Myelofibrosis

5.2.4 Spain

5.2.4.1 Assumptions and Rationale

5.2.4.2 Prevalent/Incident Cases of the of Primary Myelofibrosis in the Spain

5.2.4.3 Sub-Type Specific cases of Primary Myelofibrosis in the Spain

5.2.4.4 Sex- Specific Cases of the Primary Myelofibrosis in the Spain

5.2.4.5 Diagnosed Cases of the Primary Myelofibrosis in the Spain

5.2.4.6 Treatable Cases of the Primary Myelofibrosis

5.2.5 United Kingdom

5.2.5.1 Assumptions and Rationale

5.2.5.2 Prevalent/Incident Cases of the of Primary Myelofibrosis in the United

Kingdom

5.2.5.3 Sub-Type Specific cases of Primary Myelofibrosis in the United Kingdom

5.2.5.4 Sex- Specific Cases of the Primary Myelofibrosis in the United Kingdom

5.2.5.5 Diagnosed Cases of the Primary Myelofibrosis in the United Kingdom

5.2.5.6 Treatable Cases of the Primary Myelofibrosis

5.3 Japan

5.3.1 Assumptions and Rationale

5.3.2 Prevalent/Incident Cases of the of Primary Myelofibrosis in the Japan

5.3.3 Sub-Type Specific cases of Primary Myelofibrosis in the Japan

5.3.4 Sex- Specific Cases of the Primary Myelofibrosis in the Japan

5.3.5 Diagnosed Cases of the Primary Myelofibrosis in the Japan

5.3.6 Treatable Cases of the Primary Myelofibrosis

6 CURRENT TREATMENT & MEDICAL PRACTICES

- 6.1 Treatment Algorithm
- 6.2 Treatment Guidelines

7 UNMET NEEDS

8 MARKETED PRODUCT

- 8.1 Drug A: Company
 - 8.1.1 Drug Description
 - 8.1.2 Mechanism of Action
 - 8.1.3 Clinical Trials Details
 - 8.1.4 Advantages & Disadvantages
 - 8.1.5 Safety and Efficacy
 - 8.1.6 Product Profile
- 8.2 Drug B: Company
 - 8.2.1 Drug Description
 - 8.2.2 Mechanism of Action
 - 8.2.3 Clinical Trials Details
 - 8.2.4 Advantages & Disadvantages
 - 8.2.5 Safety and Efficacy
 - 8.2.6 Product Profile
- 8.3 Drug C: Company
 - 8.3.1 Drug Description
 - 8.3.2 Mechanism of Action
 - 8.3.3 Clinical Trials Details
 - 8.3.4 Advantages & Disadvantages
 - 8.3.5 Safety and Efficacy
 - 8.3.6 Product Profile
- 8.4 Drug D: Company
 - 8.4.1 Drug Description
 - 8.4.2 Mechanism of Action
 - 8.4.3 Clinical Trials Details
 - 8.4.4 Advantages & Disadvantages
 - 8.4.5 Safety and Efficacy
 - 8.4.6 Product Profile
- 8.5 Drug E: Company

- 8.5.1 Drug Description
- 8.5.2 Mechanism of Action
- 8.5.3 Clinical Trials Details
- 8.5.4 Advantages & Disadvantages
- 8.5.5 Safety and Efficacy
- 8.5.6 Product Profile

8.6 : Company

- 8.6.1 Drug Description
- 8.6.2 Mechanism of Action
- 8.6.3 Clinical Trials Details
- 8.6.4 Advantages & Disadvantages
- 8.6.5 Safety and Efficacy
- 8.6.6 Product Profile

8.7 : Company

- 8.7.1 Drug Description
- 8.7.2 Mechanism of Action
- 8.7.3 Clinical Trials Details
- 8.7.4 Advantages & Disadvantages
- 8.7.5 Safety and Efficacy
- 8.7.6 Product Profile

8.8 : Company

- 8.8.1 Drug Description
- 8.8.2 Mechanism of Action
- 8.8.3 Clinical Trials Details
- 8.8.4 Advantages & Disadvantages
- 8.8.5 Safety and Efficacy
- 8.8.6 Product Profile

9 EMERGING DRUGS

9.1 Key Cross Competition

9.2 Emerging company

- 9.2.1 Emerging Drug A: Company
 - 9.2.1.1 Other Development Activities
 - 9.2.1.2 Clinical Development
 - 9.2.1.3 Clinical Trials Information
 - 9.2.1.4 Safety and Efficacy
 - 9.2.1.5 Advantages and Disadvantages
 - 9.2.1.6 Product Profile

9.2.2 Emerging Drug B: Company

- 9.2.2.1 Other Development Activities
- 9.2.2.2 Clinical Development
- 9.2.2.3 Clinical Trials Information
- 9.2.2.4 Safety and Efficacy
- 9.2.2.5 Advantages and Disadvantages
- 9.2.2.6 Product Profile

9.2.3 Emerging Drug C: Company

- 9.2.3.1 Other Development Activities
- 9.2.3.2 Clinical Development
- 9.2.3.3 Clinical Trials Information
- 9.2.3.4 Safety and Efficacy
- 9.2.3.5 Advantages and Disadvantages
- 9.2.3.6 Product Profile

9.2.4 Emerging Drug D: Company

- 9.2.4.1 Other Development Activities
- 9.2.4.2 Clinical Development
- 9.2.4.3 Clinical Trials Information
- 9.2.4.4 Safety and Efficacy
- 9.2.4.5 Advantages and Disadvantages
- 9.2.4.6 Product Profile

9.2.5 Emerging Drug E: Company

- 9.2.5.1 Other Development Activities
- 9.2.5.2 Clinical Development
- 9.2.5.3 Clinical Trials Information
- 9.2.5.4 Safety and Efficacy
- 9.2.5.5 Advantages and Disadvantages
- 9.2.5.6 Product Profile

10 7MM MARKET ANALYSIS

10.1 7MM Market Size of Primary Myelofibrosis

10.2 7MM Percentage Share of Drugs Marketed for Primary Myelofibrosis

10.3 7MM Market Sales of Primary Myelofibrosis by Products

11 THE UNITED STATES MARKET OUTLOOK

11.1 Market Size of Primary Myelofibrosis in United States

11.2 Percentage Share of Drugs Marketed for Primary Myelofibrosis in United States

11.3 Market Sales of Primary Myelofibrosis by Products in United States

11.4 Analysis of Upcoming Therapies and Impact on the Market

12 EU5 COUNTRIES MARKET OUTLOOK

12.1 Market Size of Primary Myelofibrosis in EU5

12.2 Market Size of Primary Myelofibrosis in Germany

12.2.1 Market Size of Primary Myelofibrosis in Germany

12.2.2 Percentage Share of Drugs Marketed for Primary Myelofibrosis in Germany

12.2.3 Market Sales of Primary Myelofibrosis by Products in Germany

12.2.4 Analysis of Upcoming Therapies and Impact on the Market

12.3 Market Size of Primary Myelofibrosis in France

12.3.1 Market Size of Primary Myelofibrosis in France

12.3.2 Percentage Share of Drugs Marketed for Primary Myelofibrosis in France

12.3.3 Market Sales of Primary Myelofibrosis by Products in France

12.3.4 Analysis of Upcoming Therapies and Impact on the Market

12.4 Market Size of Primary Myelofibrosis in Italy

12.4.1 Market Size of Primary Myelofibrosis in Italy

12.4.2 Percentage Share of Drugs Marketed for Primary Myelofibrosis in Italy

12.4.3 Market Sales of Primary Myelofibrosis by Products in Italy

12.4.4 Analysis of Upcoming Therapies and Impact on the Market

12.5 Market Size of Primary Myelofibrosis in Spain

12.5.1 Market Size of Primary Myelofibrosis in Spain

12.5.2 Percentage Share of Drugs Marketed for Primary Myelofibrosis in Spain

12.5.3 Market Sales of Primary Myelofibrosis by Products in Spain

12.5.4 Analysis of Upcoming Therapies and Impact on the Market

12.6 Market Size of Primary Myelofibrosis in United Kingdom

12.6.1 Market Size of Primary Myelofibrosis in United Kingdom

12.6.2 Percentage Share of Drugs Marketed for Primary Myelofibrosis in United Kingdom

12.6.3 Market Sales of Primary Myelofibrosis by Products in United Kingdom

12.6.4 Analysis of Upcoming Therapies and Impact on the Market

13 THE JAPAN MARKET OUTLOOK

13.1 Market Size of Primary Myelofibrosis in Japan

13.2 Percentage Share of Drugs Marketed for Primary Myelofibrosis in Japan

13.3 Market Sales of Primary Myelofibrosis by Products in Japan

13.4 Analysis of Upcoming Therapies and Impact on the Market

14 COST ANALYSIS OF PRIMARY MYELOFIBROSIS

15 GENERIC COMPETITION IN PRIMARY MYELOFIBROSIS MARKET

16 MARKET DRIVERS

17 MARKET BARRIERS

18 REPORT METHODOLOGY

18.1 Methodology/Research Approach

18.2 Data Source

18.2.1 Secondary Sources

18.2.2 Primary Sources

I would like to order

Product name: Primary Myelofibrosis- Market Insights, Epidemiology and Market Forecast 2028

Product link: <https://marketpublishers.com/r/P07E29BE16EEN.html>

Price: US\$ 5,980.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P07E29BE16EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970